Hemolytic uremic syndrome

Patients with a history of atypical, secondary, or familial HUS should be monitored with complete blood count (CBC) and measurements of renal function after the resolution of the acute illness.

Patients with atypical HUS should have CBC, basic metabolic panel, albumin, and urinalysis performed with scheduled eculizumab infusions. There are no established guidelines on the frequency of laboratory monitoring once successfully weaned off treatment. The frequency of monitoring will vary depending on the severity of the illness and the degree of the patient's recovery.

Children with a history of Shiga toxin-producing Escherichia coli (STEC) HUS should be monitored with routine measurements of renal function and urinalysis. The frequency of testing has not been established.